学术探索
学术期刊
新闻热点
数据分析
智能评审

Salvage therapy for ovarian cancer.

被引：13
作者：
Garcia A.A. [1 ]
机构：
[1] Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, MS 34, Los Angeles, 90089-9177, CA
来源：
Current Oncology Reports | 1999年 / 1卷 / 1期
关键词：
Ovarian Cancer; Paclitaxel; Docetaxel; Clin Oncol; Epithelial Ovarian Cancer;
D O I：
10.1007/s11912-999-0012-8
中图分类号：
学科分类号：
摘要：
The majority of patients with ovarian cancer will relapse after initial chemotherapy and will be candidates for salvage treatment. Currently, five agents show clear activity in patients with platinum- and paclitaxel-resistant disease: topotecan, oral etoposide, liposomal doxorubicin, gemcitabine, and, possibly, docetaxel. In addition, other agents have activity in platinum-resistant patients: vinorelbine, tamoxifen, ifosfamide, altretamine, 5-fluorouracil with leucovorin, and, possibly, irinotecan. Furthermore, selected patients may benefit from other therapeutic approaches such as surgery or radiation therapy.
引用
收藏
页码：64 / 70
页数：6
相关论文
共 196 条
  • [1] Landis SH(1998)Cancer statistics, 1998 CA Cancer J Clin 48 6-30
  • [2] Murray T(1992)Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J Clin Oncol 10 513-514
  • [3] Bolden S(1997)Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann Oncol 8 963-968
  • [4] Markman M(1996)A randomized study in recurrent ovarian cancer comparing the efficacy of single agent vs combination chemotherapy according to time to relapse [abstract] Proc ASCO 15 279-279
  • [5] Hoskins WJ(1999)Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and resistant ovarian cancer Gynecol Oncol 72 60-64
  • [6] Eisenhauer EA(1991)Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 389-393
  • [7] Vermorken JB(1996)Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer Ann Oncol 7 1065-1070
  • [8] Glabbeke M(1998)Oxaliplatin: a review of preclinical and clinical studies Ann Oncol 9 1053-1071
  • [9] Bolis G(1996)Paclitaxel vs CAP (cyclophosphamide, adrimaycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study [abstract] Proc ASCO 15 279-279
  • [10] Scarfone G(1989)Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms Ann Intern Med 111 273-279
12345678910